Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life.
Panse J, Sicre de Fontbrune F, Burmester P, Piggin M, Matos JE, Costantino H, Wilson K, Hakimi Z, Nazir J, Desgraz R, Fishman J, Persson E, Kulasekararaj A. Panse J, et al. Among authors: sicre de fontbrune f. Eur J Haematol. 2022 Oct;109(4):351-363. doi: 10.1111/ejh.13816. Epub 2022 Jul 7. Eur J Haematol. 2022. PMID: 35746830 Free PMC article.
Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning.
Robin M, Raj K, Chevret S, Gauthier J, de Lavallade H, Michonneau D, McLornan D, Peffault de Latour R, Potter V, Kulasekararaj A, Sicre de Fontbrune F, Pagliuca A, Yakoub-Agha I, Socié G, Mufti GJ. Robin M, et al. Among authors: sicre de fontbrune f, de lavallade h. Eur J Haematol. 2018 Oct;101(4):466-474. doi: 10.1111/ejh.13085. Eur J Haematol. 2018. PMID: 29714032
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.
Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R. Röth A, et al. Among authors: sicre de fontbrune f. Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399. Blood. 2020. PMID: 31978221 Free PMC article. Clinical Trial.
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
Peipert JD, Kulasekararaj AG, Gaya A, Langemeijer SMC, Yount S, Gonzalez-Fernandez FA, Ojeda Gutierrez E, Martens C, Sparling A, Webster KA, Cella D, Tomazos I, Ogawa M, Piatek CI, Wells R, Sicre de Fontbrune F, Röth A, Mitchell L, Hill A, Kaiser K. Peipert JD, et al. Among authors: sicre de fontbrune f. PLoS One. 2020 Sep 4;15(9):e0237497. doi: 10.1371/journal.pone.0237497. eCollection 2020. PLoS One. 2020. PMID: 32886668 Free PMC article. Clinical Trial.
One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study.
Schrezenmeier H, Kulasekararaj A, Mitchell L, Sicre de Fontbrune F, Devos T, Okamoto S, Wells R, Rottinghaus ST, Liu P, Ortiz S, Lee JW, Socié G. Schrezenmeier H, et al. Among authors: sicre de fontbrune f. Ther Adv Hematol. 2020 Oct 24;11:2040620720966137. doi: 10.1177/2040620720966137. eCollection 2020. Ther Adv Hematol. 2020. PMID: 33178408 Free PMC article.
Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study.
Debureaux PE, Kulasekararaj AG, Cacace F, Silva BGP, Calado RT, Barone F, Sicre de Fontbrune F, Prata PH, Soret J, Sica M, Notaro R, Scheinberg P, Mallikarjuna V, Gandhi S, Large J, Risitano AM, Peffault de Latour R, Frieri C; Severe Aplastic Anemia Working Party of the European Group for Bone Marrow Transplantation. Debureaux PE, et al. Among authors: sicre de fontbrune f. Bone Marrow Transplant. 2021 Oct;56(10):2600-2602. doi: 10.1038/s41409-021-01372-0. Epub 2021 Jul 5. Bone Marrow Transplant. 2021. PMID: 34226670 No abstract available.
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria.
Frieri C, Peffault de Latour R, Sicre De Fontbrune F. Frieri C, et al. Among authors: sicre de fontbrune f. Expert Opin Emerg Drugs. 2022 Mar;27(1):33-43. doi: 10.1080/14728214.2022.2031973. Epub 2022 Jan 31. Expert Opin Emerg Drugs. 2022. PMID: 35078384 Review.
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective.
Sicre de Fontbrune F, Burmester P, Piggin M, Matos JE, Costantino H, Wilson K, Hakimi Z, Nazir J, Desgraz R, Fishman J, Persson E, Panse J. Sicre de Fontbrune F, et al. Hematology. 2022 Dec;27(1):1140-1151. doi: 10.1080/16078454.2022.2127630. Hematology. 2022. PMID: 36165770 Free article.
Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.
Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, Xhaard A, Rosain J, Castaneda DC, Vieira-Martins P, Roncelin S, Rodriguez-Otero P, Plessier A, Sicre de Fontbrune F, Abbes S, Robin M, Socié G. Peffault de Latour R, et al. Among authors: sicre de fontbrune f. Blood. 2015 Jan 29;125(5):775-83. doi: 10.1182/blood-2014-03-560540. Epub 2014 Dec 4. Blood. 2015. PMID: 25477495 Free article.
104 results